Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-03 20:30 | 2026-04-01 | NUVL | Nuvalent, Inc. | Balcom Alexandra | Officer | OPT+S | $105.21 | 11,430 | $1,202,526 | 85,533 |
| 2026-04-03 20:53 | 2026-04-01 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Liu Joy | Officer | SELL | $449.17 | 978 | $439,288 | 21,833 |
| 2026-04-03 20:10 | 2026-04-01 | DYN | Dyne Therapeutics, Inc. | Lucera Erick | Officer | SELL | $18.64 | 5,727 | $106,751 | 125,373 |
| 2026-04-03 20:12 | 2026-04-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Officer | SELL | $32.66 | 1,838 | $60,029 | 38,864 |
| 2026-04-03 20:07 | 2026-04-01 | BIOA | BioAge Labs, Inc. | RUBIN PAUL D | Officer | OPT+S | $17.81 | 8,820 | $157,084 | 0 |
| 2026-04-03 20:01 | 2026-04-01 | REGN | REGENERON PHARMACEUTICALS, INC. | RYAN ARTHUR F | Director | SELL | $777.27 | 100 | $77,727 | 17,603 |
| 2026-04-03 21:00 | 2026-04-02 | CAPR | CAPRICOR THERAPEUTICS, INC. | Sabar Karimah Es | Director | OPT+S | $32.00 | 7,529 | $240,928 | 0 |
| 2026-04-03 20:07 | 2026-04-01 | INSM | INSMED Inc | Adsett Roger | Officer | OPT+S | $164.63 | 88,060 | $14,497,652 | 106,810 |
| 2026-04-04 01:29 | 2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | Officer | OPT+S | $49.34 | 7,500 | $370,076 | 97,994 |
| 2026-04-04 01:30 | 2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Officer | OPT+S | $50.00 | 7,958 | $397,900 | 0 |
| 2026-04-04 01:30 | 2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | Director, Officer | SELL | $49.33 | 15,000 | $739,913 | 627,540 |
| 2026-04-03 23:46 | 2026-04-02 | IMNM | Immunome Inc. | Rosett Max | Officer | OPT+S | $21.92 | 65,000 | $1,424,917 | 54,037 |
| 2026-04-03 23:48 | 2026-04-02 | IMNM | Immunome Inc. | Higgins Jack | Officer | SELL | $21.64 | 9,438 | $204,238 | 22,000 |
| 2026-04-03 22:17 | 2026-04-02 | WHWK | Whitehawk Therapeutics, Inc. | Lennon David James | Director, Officer | OPT+S | $3.48 | 26,858 | $93,466 | 793,549 |
| 2026-04-03 21:57 | 2026-04-02 | ZLAB | Zai Lab Ltd | Amado Rafael | Officer | OPT+S | $20.39 | 9,910 | $202,065 | 59,761 |
| 2026-04-03 21:57 | 2026-04-02 | ZLAB | Zai Lab Ltd | Chen Yajing | Officer | OPT+S | $20.39 | 5,199 | $106,008 | 32,558 |
| 2026-04-03 21:58 | 2026-04-02 | ZLAB | Zai Lab Ltd | Du Ying | Director, Officer | OPT+S | $20.39 | 5,576 | $113,695 | 1,125,279 |
| 2026-04-03 21:58 | 2026-04-02 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | Officer | OPT+S | $20.39 | 4,194 | $85,516 | 24,590 |
| 2026-04-03 21:59 | 2026-04-02 | ZLAB | Zai Lab Ltd | Smiley Joshua L | Officer | OPT+S | $20.39 | 9,614 | $196,029 | 120,619 |
| 2026-04-03 21:45 | 2026-04-01 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | Officer | SELL | $5.99 | 16,667 | $99,859 | 1,209,840 |
| 2026-04-03 21:46 | 2026-04-01 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Director | SELL | $23.88 | 10,000 | $238,801 | 39,744 |
| 2026-04-03 21:09 | 2026-04-01 | JAZZ | Jazz Pharmaceuticals plc | COZADD BRUCE C | Director | SELL | $190.50 | 6,000 | $1,143,010 | 384,682 |
| 2026-04-03 21:20 | 2026-04-01 | PTCT | PTC THERAPEUTICS, INC. | Almstead Neil Gregory | Officer | SELL | $69.04 | 52,003 | $3,590,240 | 60,137 |
| 2026-04-03 21:06 | 2026-04-02 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Director | BUY | $2.10 | 713,800 | $1,498,980 | 3,288,539 |
| 2026-04-03 20:05 | 2026-04-01 | EBS | Emergent BioSolutions Inc. | Williams Paul Anthony | Officer | SELL | $8.44 | 4,000 | $33,760 | 62,681 |
| 2026-04-03 19:13 | 2026-04-01 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Officer | OPT+S | $16.00 | 679 | $10,864 | 3,622 |
| 2026-04-03 19:14 | 2026-04-01 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | Officer | SELL | $16.96 | 15,959 | $270,593 | 17,338 |
| 2026-04-03 13:00 | 2026-04-01 | ERAS | Erasca, Inc. | Garner Ebun | Officer | OPT+S | $16.40 | 80,000 | $1,312,000 | 25,076 |
| 2026-04-02 21:58 | 2026-04-01 | RPRX | Royalty Pharma plc | Coyne Terrance P. | Officer | SELL | $48.33 | 34,791 | $1,681,512 | 32,916 |
| 2026-04-02 20:39 | 2026-04-01 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | Officer | SELL | $12.95 | 2,500 | $32,375 | 119,010 |
| 2026-04-02 21:12 | 2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Neal James R | Director | BUY | $2.54 | 789 | $2,000 | 818 |
| 2026-04-02 21:55 | 2026-04-01 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | Director, Officer | OPT+S | $30.93 | 60,000 | $1,855,842 | 432,886 |
| 2026-04-02 20:29 | 2026-04-01 | BMY | BRISTOL MYERS SQUIBB CO | Elkins David V | Officer | SELL | $61.67 | 30,000 | $1,850,016 | 159,248 |
| 2026-04-02 21:55 | 2026-04-01 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | Officer | OPT+S | $30.00 | 10,000 | $300,000 | 105,211 |
| 2026-04-03 01:00 | 2026-03-31 | ADCT | ADC Therapeutics SA | Redmile Group, LLC | 10% owner | SELL | $3.34 | 5,880,415 | $19,636,470 | 10,265,297 |
| 2026-04-03 00:09 | 2026-04-01 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Officer | OPT+S | $21.20 | 27,000 | $572,478 | 112,622 |
| 2026-04-02 23:43 | 2026-04-01 | LGND | LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W | Director | SELL | $202.23 | 467 | $94,440 | 42,253 |
| 2026-04-02 23:43 | 2026-04-02 | IONS | IONIS PHARMACEUTICALS INC | Devers Shannon L. | Officer | SELL | $74.05 | 6,193 | $458,613 | 16,348 |
| 2026-04-02 23:43 | 2026-04-01 | IONS | IONIS PHARMACEUTICALS INC | KLEIN JOSEPH III | Director | OPT+S | $75.55 | 22,321 | $1,686,302 | 11,014 |
| 2026-04-02 22:53 | 2026-03-31 | MLYS | Mineralys Therapeutics, Inc. | Karydas Daphne | Director | OPT+S | $25.00 | 3,000 | $75,000 | 6,200 |
| 2026-04-02 22:54 | 2026-03-31 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | Director, Officer | SELL | $26.27 | 75,000 | $1,970,520 | 705,051 |
| 2026-04-02 22:56 | 2026-04-01 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | Officer | OPT+S | $201.24 | 5,000 | $1,006,224 | 41,382 |
| 2026-04-02 23:02 | 2026-04-02 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | Officer | SELL | $15.24 | 8,148 | $124,149 | 26,453 |
| 2026-04-02 22:15 | 2026-04-01 | TERN | Terns Pharmaceuticals, Inc. | Kuriakose Emil | Officer | SELL | $52.75 | 942 | $49,693 | 105,673 |
| 2026-04-02 22:19 | 2026-04-01 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | Officer | SELL | $20.97 | 4,683 | $98,203 | 80,351 |
| 2026-04-02 21:02 | 2026-03-31 | ZBIO | Zenas BioPharma, Inc. | Lu Hongbo | Director | BUY | $18.63 | 3,768 | $70,198 | 426,736 |
| 2026-04-02 21:05 | 2026-04-02 | LPCN | Lipocine Inc. | Patel Mahesh V. | Director, Officer | BUY | $2.02 | 25,000 | $50,500 | 135,679 |
| 2026-04-02 20:48 | 2026-03-31 | MLTX | MoonLake Immunotherapeutics | BVF PARTNERS L P/IL | Director, 10% owner | SELL | $16.79 | 3,750,000 | $62,962,500 | 1,039,238 |
| 2026-04-02 20:34 | 2026-03-31 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $585.76 | 9,500 | $5,564,709 | 40,513 |
| 2026-04-02 20:35 | 2026-04-01 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $581.63 | 9,500 | $5,525,526 | 40,513 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.